alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Disease mechanisms in lab and animal studies

1,352 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Active amyloid beta immunization ameliorates synapse loss and phosphorylated-tau accumulation around remaining plaques for up to 14 years after treatment

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-08-11 Treatments

    Amyloid plaques, one of the defining features of Alzheimer’s disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity.

  2. A New Frontier in CWD Detection: Antemortem Plasma Biomarkers and Behavioral Profiling in Transgenic Mouse Models

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-10 Biomarkers

    Chronic Wasting Disease (CWD) is a fatal transmissible spongiform encephalopathy (TSE) that is confined to cervids (deer, moose, elk, and reindeer) but shares key properties with human neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Huntington’s disease and frontal-temporal dementia.

  3. APP Dosage and Extracellular Domain Variants Drive Distinct Defects in Neurogenesis modeled in Down Syndrome iPS cells

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-06 Down syndrome and Alzheimer's

    The amyloid precursor protein (APP) is heavily studied as the source of amyloid beta in Alzheimer’s disease (AD), however, the complex functions of APP remain poorly understood, as does the impact of APP dosage on neurodevelopment.

  4. Early Amyloid-β Toxicity Disrupts Nervous System Connectivity During Aging in Caenorhabditis elegans

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-29 Treatments

    Our experiments revealed that nAβ expressing animals exhibit a unique loss of positively correlated neuron connectivity, premature disruption of system wide dynamics, and reduced overall neuronal activity.

  5. Deep nanoparticle protein corona plasma proteomics resolves a stage-specific peripheral signature of Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-28 Brain scans and imaging

    Structured Abstract INTRODUCTION Alzheimer’s disease (AD) progresses over decades, yet plasma biomarkers that resolve disease stage rather than simply detect disease remain scarce.

  6. Computational Screening of 1,348 FDA-Approved Drugs as Potential BACE1 Inhibitors for Alzheimer's Disease Drug Repurposing

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-28 Drug development

    Alzheimer's disease (AD) remains one of the most devastating and economically costly neurological conditions of the modern era, affecting over 55 million individuals worldwide with no approved disease-modifying therapy.

  7. Chronic orexin receptor antagonism is associated with rescued sleep and agitation-like behaviour in tau transgenic PS19 mice, but sex-dependently improved cognition

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Authorea Preprints 2026-07-25 Risk factors

    DORA-22 and MK-1064 rescued tauopathy-related sleep loss, and reduced agitation-like locomotion and stress-induced hyperthermic responses.

  8. Cobalt-Based Drug Delivery to the Brain using Rapid Short-Pulses of Focused Ultrasound and Microbubbles reduces Aβ aggregation in 5XFAD mice

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-24 Treatments

    A major obstacle to effective Alzheimer’s disease therapy is the limited ability to deliver therapeutics across the blood-brain barrier.

  9. Alzheimer disease β-amyloid pathology accelerates age-related hearing loss: evidence from App NL-F “knock-in” mice

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-05-28 Risk factors

    Age-related hearing loss (ARHL) is a main acquired risk factor for dementia, including Alzheimer disease (AD), but links are unknown.

  10. Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cells

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-02-05 Down syndrome and Alzheimer's

    Dysregulated expression and activity of DYRK1A, dual specificity tyrosine phosphorylation regulated kinase 1A, is a feature of several neurodevelopmental and neurodegenerative diseases, including Down syndrome, DYRK1A syndrome, autism spectrum disorders, Alzheimer’s disease, and Parkinson’s disease.

  11. Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-01-06 Drug development

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles.

  12. A Biophysical Framework for Neurodegeneration: Prioritizing Protein Homeostasis Over Aggregate Toxicity

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2025-12-31 Treatments

    Neurodegenerative research has long hypothesized that aggregated proteins such as amyloid‑β (Aβ), tau, and α‑synuclein (αSyn) are intrinsically toxic and are directly associated with the etiologies of Alzheimer’s disease (AD) and Parkinson’s disease (PD).

  13. Conformation-based detection of tau seeds with a novel VHH

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-12-08 Drug development

    In Alzheimer’s disease (AD) and related tauopathies, progressive pathology has been linked to prion mechanisms whereby ordered tau assemblies, or “seeds,” form in one cell and transit to neighboring or connected cells where they serve as templates for their own replication.

  14. Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research square 2025-12-03 Brain tissue and pathology

    Tau pathology, characterized by the aberrant aggregation and accumulation of tau in neurons and glial cells, plays a critical role in the onset and progression of multiple neurodegenerative diseases.

  15. Nanobodies targeting hnRNPA2/B1 and tau

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv : the preprint server for biology 2025-11-24 Drug development

    Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1) is an RNA-binding protein that mislocalizes to the cytoplasm and forms stress-induced granules in tauopathy and multisystem proteinopathy.

  16. Generation of a recombinant GST-Tau antigen for indirect ELISA in evaluating Alzheimer’s disease vaccines

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2025-09-20 Drug development

    A robust method was developed to produce and optimize GST-Tau as a coating antigen for indirect ELISA.

  17. mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-09-16 Drug development

    Current Alzheimer’s disease (AD) immunotherapeutics face efficacy and safety limitations with antibody-based approaches.

  18. Amyloid precursor protein dosage normalization rescues neurogenesis and Alzheimer’s Disease phenotypes associated with Down Syndrome

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2025-07-30 Down syndrome and Alzheimer's

    Down Syndrome (DS) is the most abundant genetic form of mental retardation.

  19. Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in Tauopathies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2025-07-04 Drug development

    Tauopathies are neurodegenerative diseases characterized by pathological tau accumulation, leading to motor and neuropsychiatric symptoms.

  20. In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Authorea Preprints 2025-06-03 Drug development

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by abnormal aggregation of the tau protein.

  21. Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research square 2024-07-23 Disease mechanisms

    This study explored the role of the ubiquitin-proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining changes in cerebrospinal fluid (CSF) levels of UPS proteins along with disease progression, AD imaging biomarkers (PiB PET, tau PET), neurodegeneration imaging measures (MRI, FDG PET), and Clinical Dementia Rating® (CDR®).

  22. Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv : the preprint server for biology 2024-02-03 Drug development

    Microtubule-associated protein tau is an intrinsically disordered protein (IDP) that forms characteristic fibrillar aggregates in several diseases, the most well-known of which is Alzheimer's disease (AD).

  23. Frontotemporal Dementia Patient Neurons With Progranulin Deficiency Display Protein Dyshomeostasis

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv : the preprint server for biology 2023-01-20 Disease mechanisms

    Haploinsufficiency of progranulin (PGRN) causes frontotemporal dementia (FTD), a devastating neurodegenerative disease with no effective treatment.

  24. Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer's disease

    ⚠ Retracted — do not rely on it alzhub usefulness score 15 out of 100. Journal of nanobiotechnology 2020-05-13 Drug development

    Intravenous neuronal tau-targeted T807-modified novel biomimetic nanosystems are a promising clinical candidate for the treatment of AD.

  25. Pericyte loss influences Alzheimer-like neurodegeneration in mice

    ⚠ Retracted — do not rely on it alzhub usefulness score 13 out of 100. Nature communications 2013-01-01 Vascular contributions

    Pericytes are cells in the blood-brain barrier that degenerate in Alzheimer's disease (AD), a neurological disorder associated with neurovascular dysfunction, abnormal elevation of amyloid β-peptide (Aβ), tau pathology and neuronal loss.

From across this topic

10 of the 1,352 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics